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JOURNAL OF HEPATOLOGYTo the Editor:
In a retrospective cohort, Janse et al. [1] analyzed the association
of malignancies with the presence of inﬂammatory bowel disease
(IBD) and dominant stenosis (DS) in patients with primary scle-
rosing cholangitis (PSC). We have analyzed and published on
these associations in our prospective cohort, previously [2]. The
present study of Janse et al. essentially conﬁrms our data in a ret-
rospective evaluation.
Both studies acquired data on the number of carcinomas
(cholangiocarcinoma, gallbladder carcinoma, and colorectal car-
cinoma) and analyzed a potential association with the concomi-
tant presence of DS and/or IBD in these patients. We found the
highest frequency of carcinomas in the group of patients having
both DS and IBD of 20.9% (14/67); in the retrospective cohort of
Janse et al., this group also had the highest number of carcinomas
with a rate of 23.6% (13/55). The second highest frequency of car-
cinomas was found in both studies in the group of patients
having DS irrespective of the presence of IBD (our study: 14.4%
(14/97); Janse study: 18.2% (14/77)), and the third highest fre-
quency in both studies was that of IBD patients irrespective of
the presence of DS (our study: 12.5% (15/120); Janse study
13.8% (22/160)). The overall number of carcinomas appears
somewhat higher in the cohort reported by Janse et al. [1], which
at least in part might be attributed to the referral bias of a large
tertiary care center focused on liver transplantation.
From their data, Janse et al. draw the conclusions that their
results are different from ours and that there is no difference in
IBD-patients whether they have DS or not. Although the p value
is not explicitly mentioned in the text, in both studies the differ-
ence between patients with and without DS is signiﬁcant (our
study: 14/53 vs. 1/51 p = 0.002; Janse study: 13/55 vs. 9/105
p = 0.009). Thus, the data of Janse et al. conﬁrm our data and
our conclusion that DS is associated with more carcinomas.
According to Janse et al., the number of carcinomas in the
patients without dominant stenosis was higher than in our study
but it seems to us difﬁcult to evaluate such data retrospectively
and therefore we do not believe that the two studies are comparable.
In both studies, the frequency of carcinomas was higher in the
DS group than in the IBD group and was even higher in the group
having the combination of IBD and DS (see frequencies above).
This of course does not exclude that IBD plays a substantial role.
Janse et al. argue that in their study deﬁnitions of dominant
stenosis might have some problems. Information on this topic
appears essential (screening for DS by ERC?), since it will mark-
edly affect the results. Deﬁnitions of DS are now implemented
in the allocation system of Eurotransplant and are accepted both
by the AASLD and EASL guidelines [3–5].
Lastly, we would like to mention a potential role of UDCA
treatment which was performed in all of our patients. AlthoughJournal of Hepatology 2the anti-neoplastic potential of UDCA has been under debate,
especially in very high doses, such an effect may inﬂuence the
incidence of malignancies [6–9].
We agree with Janse et al. that surveillance in patients with
PSC should be performed according to current guidelines. Our
study and that of Janse et al. indicate that patients with dominant
stenoses are at an increased risk of malignancy.012 vol. 57 j 467–477 475
